News & Events
-
November 5, 2018
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease
Critical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy development for AD and related forms of dementia TUCSON, Ariz., November 5, 2018 — The Critical Path Institute (C-Path) is pleased to announce that its Critical Path for Alzheimer’s Disease (CPAD) consortium has refined and refocused its mission in celebration of... -
November 1, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
Kenna, J. Gerry, Kunal S. Taskar, Christina Battista, David L. Bourdet, Kim L.R. Brouwer, Kenneth R. Brouwer, David Dai, et al. “Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.” Clinical Pharmacology and Therapeutics104, no. 5 (November 2018): 916–32.
-
November 1, 2018
C-Path, CHDI and CDISC Announce Therapeutic Area User Guide for Huntington’s Disease
TUCSON, Ariz., NEW YORK and AUSTIN, Texas, November 1, 2018 — The Huntington’s Disease Regulatory Science Consortium (HD-RSC), launched in March 2018 by the Critical Path Institute (C-Path) and CHDI Foundation, today, along with the Clinical Data Interchange Standards Consortium (CDISC), announce the open availability of a newly developed Huntington’s Disease Therapeutic Area User Guide... -
October 30, 2018
Webinar Recording Available: Acetaminophen-Induced Liver Toxicity Mechanisms, Diagnosis and Treatment
Members of C-Path’s Predictive Safety Testing Consortium (PSTC) were among the featured facilitators and speakers of an educational webinar, sponsored and hosted by the Clinical and Translational Toxicology Specialty Section of the Society of Toxicology, on acetaminophen (APAP) induced liver toxicity. With a duration of 1 hour and 12 minutes, this Oct. 30, 2018 event... -
October 25, 2018
FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug Administration
Major Milestone will Improve Detection of Drug-Induced Acute Kidney Injury in Clinical Trials. October 25, 2018 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC) have received the first ever qualification of a clinical safety biomarker awarded by...